Last $1.72 USD
Change Today -0.04 / -2.27%
Volume 30.4K
ECTE On Other Exchanges
As of 8:10 PM 09/15/14 All times are local (Market data is delayed by at least 15 minutes).

echo therapeutics inc (ECTE) Snapshot

Previous Close
Day High
Day Low
52 Week High
11/26/13 - $4.91
52 Week Low
05/28/14 - $1.53
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ECHO THERAPEUTICS INC (ECTE)

Related News

No related news articles were found.

echo therapeutics inc (ECTE) Related Businessweek News

No Related Businessweek News Found

echo therapeutics inc (ECTE) Details

Echo Therapeutics, Inc. is engaged in the development of transdermal skin permeation and diagnostic medical devices. It is developing Symphony CGM system (Symphony), a needle-free wireless continuous glucose monitoring system for use in hospital critical care units; and Symphony SkinPrep system, a component of its Symphony for enhanced skin permeation that enables extraction of analytes, such as glucose. The company is also engaged in the development Durhalieve, an AzoneTS formulation of triamcinolone acetonide that has completed Phase III clinical trials for the treatment of corticosteroid-responsive dermatoses. It has a licensing agreement with Ferndale Pharma Group, Inc. to develop, market, sell, and distribute Prelude SkinPrep system for skin preparation prior to the application of topical anesthetics prior to a range of needle-based medical procedures in North America, the United Kingdom, South America, Australia, New Zealand, Switzerland, and other portions of the European Community; a license agreement with Handok Pharmaceuticals Co., Ltd. to develop, use, market, import, and sell Symphony for continuous glucose monitoring for use by medical facilities and/or individual consumers in South Korea; and a license, development, and commercialization agreement with Medical Technologies Innovation Asia, Ltd. The company was founded in 1989 and is headquartered in Philadelphia, Pennsylvania.

28 Employees
Last Reported Date: 03/28/14
Founded in 1989

echo therapeutics inc (ECTE) Top Compensated Officers

Chief Compliance Officer, Senior Vice Preside...
Total Annual Compensation: $220.0K
Compensation as of Fiscal Year 2013.

echo therapeutics inc (ECTE) Key Developments

Echo Therapeutics Cut its Workforce by 35%

Echo Therapeutics has cut its workforce by 35% as part of an effort to reduce operating costs and preserve cash so it can focus its resources on developing its Symphony continuous glucose monitoring system.

Echo Therapeutics, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Echo Therapeutics, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported total revenues of $19,107 against $22,557 a year ago. Loss from operations was $3,915,482 against $6,094,939 a year ago. Net loss was $3,763,976 or $0.31 per basic and diluted share against $3,341,397 or $0.51 per basic and diluted share a year ago. For the six months, the company reported total revenues of $38,214 against $45,114 a year ago. Loss from operations was $6,585,183 against $11,591,552 a year ago. Net loss was $6,537,017 or $0.55 per basic and diluted share against $10,329,722 or $1.73 per basic and diluted share a year ago.

Echo Therapeutics, Inc. Approves Amendments to Bylaws

On July 24, 2014, the Board of Directors of Echo Therapeutics, Inc. approved amendments to the company's bylaws, effective as of July 24, 2014. The Amended Bylaws were amended to provide that special meetings of the Board of Directors shall be held at the written request of at least three directors then in office, including, as one of those directors, the Lead Independent Director.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ECTE:US $1.72 USD -0.04

ECTE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $42.72 USD +0.17
Bayer AG €106.25 EUR -0.31
Johnson & Johnson $104.72 USD +0.14
Roche Holding AG SFr.275.70 CHF -0.10
View Industry Companies

Industry Analysis


Industry Average

Valuation ECTE Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1,026.3x
Price/Book 1.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 877.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ECHO THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at